New Aid for AIDS - ICAP Ocean Tomo Announces Auction of a Keystone Patent for Cell Therapy Use of Modified Red Blood Cells for Treating Viral Diseases
CHICAGO, March 14, 2011 /PRNewswire/ -- Developed by inventor Lawrence F. Glaser and represented by ICAP Ocean Tomo, this technology will be auctioned off at ICAP Ocean Tomo's Spring 2011 Live IP Auction on March 31, 2011 in New York City.
Key Characteristics & Benefits
This patent discloses the following:
- The use of genetically modified erythrocytes/red blood cells (RBC) for treating and preventing viral infections. Modified cells can also be generated through non-recombinant low-cost means, such as with ghosting techniques using mature patient or donor cells.
- A desired protein receptor/coreceptor may be introduced into precursor cells using a gene transfer technique, such as transfection, transduction, and gene gun. These modified precursor cells can then be cultured in a suitable environment to generate the desired erythrocyte having a specific protein receptor complex, used as a trap for treating a target viral infection.
- The disclosed erythrocytes comprise HIV receptors capable of mediating HIV entry into the modified cells. When these modified erythrocytes are administered to an HIV+ patient, the erythrocytes attract and absorb HIV, uncloaking each viral particle preventing further viral infection through direct depletion of viral load.
- The entrapped virus is subsequently degraded and deactivated within the erythrocytes, assuring entrapment. Red Cells are eliminated through the natural cycle, Erythrophagocytosis, shown in research studies to completely disintegrate any payload.
- The modified erythrocytes can be prepared from the erythrocyte
precursor cells isolated from peripheral blood, bone marrow,